TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24474552
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water (355 mL)
Study: 21961239
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of 2 ml of 80,000 U gentamycin + 2 ml of lidocaine, twice a week for 3 weeks
Study: 21961239
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline + 2 ml of lidocaine, twice a week for 3 weeks (Control Group B)
Study: 21961239
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline + 2 ml of lidocaine, twice a week for 3 weeks (Control Group C)
Study: 17344487
Drug: Medium Calcium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Calcium meal (MC meal: 84 mg/MJ)
Study: 17344487
Drug: High Calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Calcium meal (HC meal: 172 mg/MJ)
Study: 17344487
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplement (Suppl meal: 183 mg/MJ)
Study: 2444241
Drug: Extradural administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural administration of meptazinol 90 mg
Study: 2444241
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) administration of meptazinol 90 mg
Study: 26391263
Drug: Combined TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined TXA (1 g IV + 2 g local)
Study: 26391263
Drug: IV TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV TXA (1.5 g)
Study: 26391263
Drug: Local TXA
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local TXA (3 g)
Study: 10817726
Drug: AMD-3100 intravenous
Normalized name: AMD
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMD-3100 intravenous infusion at 10, 20, 40, or 80 microg/kg
Study: 10817726
Drug: AMD-3100 subcutaneous
Normalized name: AMD
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMD-3100 subcutaneous injection at 40 or 80 microg/kg
Study: 10817726
Drug: AMD-3100 oral
Normalized name: AMD
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMD-3100 oral dosing at 80 and 160 microg/kg
Study: 10817726
Drug: AMD-3100 intravenous
Normalized name: AMD
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMD-3100 intravenous dose at 80 microg/kg
Study: 10817726
Drug: AMD-3100 intravenous
Normalized name: AMD
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AMD-3100 intravenous dose
Study: 8877991
Drug: Octreotide 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.10 mg
Study: 8877991
Drug: Octreotide 0.05
Normalized name: octreotide 0.05 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.05 mg
Study: 8877991
Drug: Octreotide 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.10 mg and 0.05 mg
Study: 1839442
Drug: Diltiazem (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (30 mg three times daily)
Study: 28492790
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard therapy only)
Study: 29291429
Drug: Phytosterols (PS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterols (PS, 2 g/d)
Study: 29291429
Drug: Curcumin (CC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (CC, 200 mg/d)
Study: 29291429
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PS and Curcumin (PS-CC, 2 g/d-200 mg/d)
Study: 2071257
Drug: L-alpha-glycerylphosphorylcholine (L-alpha-GFC)
Normalized name: L-alpha-Glycerophosphorylcholine
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alpha-glycerylphosphorylcholine (L-alpha-GFC)
Study: 6395907
Drug: Relaxation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation treatment (modified PMR and imagery exercises)
Study: 29661902
Drug: 0.45 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg/d oral conjugated equine estrogen (oCEE)
Study: 29661902
Drug: 50 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg/d transdermal 17β‐estradiol (tE2)
Study: 26171861
Drug: 10 grams
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 grams of oral creatine/day
Study: 20666269
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with amlodipine and fosinopril given in the morning and at bedtime (group A)
Study: 20666269
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of amlodipine and fosinopril in the morning (group B)
Study: 18789680
Drug: Berberine plus
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine plus radiation therapy
Study: 18789680
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus radiation therapy
Study: 12663231
Drug: Probucol 500
Normalized name: probucol 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol 500 mg daily for 6 months
Study: 11115310
Drug: Sequential mail/telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential mail/telephone reminder group
Study: 1465591
Drug: Norfloxacin (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (active drug)
Study: 6437343
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of FT‐207 suppository (Group A)
Study: 6437343
Drug: Preoperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative and postoperative administration of FT‐207 suppository (Group B)
Study: 26709596
Drug: Modified-release (MR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release (MR) formulations of omecamtiv mecarbil (25 mg)
Study: 26709596
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation of omecamtiv mecarbil (25 mg)
Study: 24828092
Drug: Conventional subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subunit vaccine (Agrippal S1; Novartis)
Study: 24828092
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine (Fluad; Novartis)
Study: 24828092
Drug: Intradermal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccine (IDflu15; Sanofi Pasteur)
Study: 22183975
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment (methotrexate 0.5 mg/kg/week, etanercept 0.8 mg/kg/week, prednisolone 0.5 mg/kg/day tapered to 0 by 17 weeks)
Study: 22183975
Drug: Methotrexate (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (same dosage as arm 1), etanercept placebo, and prednisolone placebo
Study: 17760981
Drug: Standardised physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised physiotherapy treatment of advice and exercises for the arm and shoulder for three months
Study: 17760981
Drug: Standardised physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised physiotherapy treatment
Study: 12146772
Drug: Sustained Achilles
Normalized name: Bos taurus achilles tendon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained Achilles tendon stretches (3 minutes, 3 times daily)
Study: 12146772
Drug: Intermittent Achilles
Normalized name: Bos taurus achilles tendon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Achilles tendon stretches (5 sets, 20 seconds each, 2 times daily)
Study: 1035149
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline in combination with a topical sodium sulfacetamide-sulfur-hydro-cortisone lotion
Study: 23861993
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4 g/day for 12 months)
Study: 21287196
Drug: Strength trained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength trained individuals (L(opt) 9.7% BW)
Study: 21287196
Drug: Speed trained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speed trained individuals (L(opt) 9.2% BW)
Study: 21287196
Drug: Physically active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physically active individuals (L(opt) 8.7% BW)
Study: 21287196
Drug: Sedentary individuals
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sedentary individuals (L(opt) 8.0% BW)
Study: 17451642
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) for CFS
Study: 15483071
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g high‐isoflavone soy protein (SOY)
Study: 11666130
Drug: Nadroparin calcium
Normalized name: nadroparin calcium
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin calcium followed by adjunctive oral aspirin for 6 months
Study: 2531901
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ramipril once daily for 7 days
Study: 2531901
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 7 days
Study: 31909554
Drug: 300 g/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g/l PEG (drought stress)
Study: 28012633
Drug: Dexamethasone (4mg/ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4mg/ml, 1ml) administered 15min before surgery
Study: 28012633
Drug: Dexamethasone (4mg/ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4mg/ml, 1ml) administered 15min after surgery
Study: 28012633
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 15min before and after surgery
Study: 24555998
Drug: HBV envelope‐expressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV envelope‐expressing DNA vaccine (5 intramuscular injections at weeks 0, 8, 16, 40, and 44)
Study: 24555998
Drug: HBV envelope‐expressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV envelope‐expressing DNA vaccine
Study: 19358927
Drug: crocetin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: crocetin (15 mg)
Study: 19358927
Drug: ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ascorbic acid (3,000 mg)
Study: 12585168
Drug: Colquhounia root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colquhounia root tablet (CRT)
Study: 12585168
Drug: Hormone or
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone or cytotoxic medicine (Control)
Study: 9584030
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of methadone with 5 visits per week
Study: 9584030
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of methadone with fewer visits
Study: 9584030
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of methadone
Study: 2647605
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of porcine GIP (2 pmol.kg‐1.min‐1)
Study: 352210
Drug: Inactivated bivalent
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated bivalent (A/NJ and A/Victoria) influenza vaccine
Study: 28525512
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg at the end of surgery and then every 12 hours for 3 days)
Study: 19096945
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of sterile water
Study: 15504182
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 7.5 mg with sufentanil 5 microg
Study: 15504182
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 15 mg
Study: 9259608
Drug: Immunochemical method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemical method (ELISA) for detecting P. carinii antibodies
Study: 30972018
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg fasudil
Study: 30972018
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg fasudil
Study: 30972018
Drug: Fasudil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (30 mg or 60 mg)
Study: 30049304
Drug: Desmopressin oral
Normalized name: desmopressin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin oral tablet (0.6 mg; 0.2 mg × 3) under fed conditions
Study: 30049304
Drug: Desmopressin oral
Normalized name: desmopressin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin oral tablet (0.6 mg; 0.2 mg × 3) under fasted conditions
Study: 19914369
Drug: EG 500
Normalized name: Prosys Leg 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG 500 (500 mg of Campomanesia xanthocarpa)
Study: 19914369
Drug: EG 250
Normalized name: Gris-PEG 250mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG 250 (250 mg of Campomanesia xanthocarpa)
Study: 19914369
Drug: CG (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG (placebo capsules)
Study: 10066008
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication plus exposure
Study: 8952328
Drug: Improved Estimated
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved Estimated Ecological Daily Intake (EEDI) method for estimating daily intake of food contaminants and additives.
Study: 8952328
Drug: Improved EEDI
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved EEDI method for estimating daily intake of environmental contaminants.
Study: 6478471
Drug: Acebutolol, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol, 50 mg
Study: 6478471
Drug: Propranolol, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 10 mg
Study: 28760152
Drug: S-1 maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 maintenance therapy
Study: 30101439
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg TFV film
Study: 30101439
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg TFV film
Study: 30101439
Drug: TFV 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFV 1% gel
Study: 23006462
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for a variable period of 1-12 years
Study: 19947406
Drug: Short-wave therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-wave therapy included in rehabilitative program
Study: 17179770
Drug: N-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-3 polyunsaturated fatty acids (PUFAs) - 2 capsules containing 1 g of fish oil 3 times daily (n = 60)
Study: 17179770
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 1 g of paraffin oil capsules (n = 62)
Study: 17179770
Drug: N-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-3 polyunsaturated fatty acids (PUFAs) - patients with baseline TG levels >10 g/L
Study: 15123223
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (SLM/FP) 50 microg and 500 microg Diskus, 1 inhalation twice daily
Study: 15123223
Drug: Theophylline (THEO)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline (THEO) plus fluticasone propionate (FP) 500 microg Diskus, 1 inhalation twice daily
Study: 9678714
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (HDMP, 900-600 mg/m2 orally)
Study: 9678714
Drug: Conventional-dose prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose prednisolone (2 mg/kg/day orally)
Study: 28000311
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIG) 0.4 g/kg/week for 5 weeks
Study: 21745374
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days
Study: 26555352
Drug: High-dose intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intradermal TIV
Study: 12054149
Drug: Sublingual fentanyl
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual fentanyl citrate (SLFC)
Study: 11326965
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation (10 ppm for 30 min)
Study: 11326965
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg, tid) in addition to conventional therapy
Study: 11326965
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (oxygen, intravenous furosemide, aminophylline, dexamethasone)
Study: 7827638
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 (0.05 mg/24 h)
Study: 7827638
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 (0.05 mg/24 h) + Nomegestrol acetate (5 mg/24 h)
Study: 7827638
Drug: E2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 treatment (after 2 weeks)
Study: 7827638
Drug: E2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 treatment (3rd month)
Study: 3287675
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg or 1,200 mg daily for a mean duration of 35 months
Study: 3287675
Drug: Placebo (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (not taking aspirin)
Study: 30303905
Drug: Torsemide 20
Normalized name: torsemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide 20 mg/d for 5 days
Study: 26049866
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg cranberry powder (Flowens™)
Study: 26049866
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg cranberry powder (Flowens™)
Study: 17347010
Drug: Before GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before GH replacement therapy
Study: 17347010
Drug: During GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: During GH replacement therapy
Study: 7544628
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration starting on day 0 (group A)
Study: 7544628
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration starting on day +7 (group B)
Study: 7544628
Drug: G-CSF administration
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF administration (both groups)
Study: 550376
Drug: 250 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 micrograms salbutamol (bolus intravenous injection)
Study: 30661551
Drug: MATCH (modular
Approvals — FDA: no, EMA: no, PMDA: no
Description: MATCH (modular evidence-based treatment)
Study: 23370978
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine spray
Study: 20027938
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate cream (Cutivate)
Study: 19839994
Drug: Risperidone 0.5-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 0.5-2.5 mg/day
Study: 19839994
Drug: Risperidone 3-6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 3-6 mg/day
Study: 15898029
Drug: Medial canthus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial canthus single-injection peribulbar anesthesia
Study: 15898029
Drug: Double-injection peribulbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-injection peribulbar anesthesia
Study: 9615558
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus daily OMT (10 to 20 minutes daily)
Study: 7648588
Drug: Low osmolar
Normalized name: Watersoluble, nephrotropic, low osmolar X-ray contrast media
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low osmolar contrast material (Omnipaque 240 mgI/ml) (n = 33)
Study: 338089
Drug: Prophylactic low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic low dose subcutaneous calcium heparin (dose based on body weight)
Study: 30157383
Drug: Bacteriophage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriophage treatment (15 mg capsule containing 4 strains of bacteriophages)